The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study

Journal of the American Academy of Dermatology

Volumn 74, Issue 4, 2016, Pages 693-699.e3

  Chasset, François ^a   Arnaud, Laurent ^b,c   Costedoat Chalumeau, Nathalie ^d,e   Zahr, Noel ^b   Bessis, Didier ^f   Francès, Camille ^a  

^a HÔPITAL TENON   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e Institut Cochin   (France)

^f UNIV MONTPELLIER   (France)

Author keywords

antimalarials; cutaneous lupus erythematosus; hydroxychloroquine; hydroxychloroquine blood concentration; increasing dose; retinal toxicity

Indexed keywords

CORTICOSTEROID; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLATE MOFETIL; TACROLIMUS; ANTIMALARIAL AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFRACTORY SKIN LUPUS ERYTHEMATOSUS; RELAPSE; RETINOPATHY; SKIN LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; CHRONIC DISEASE; DOSE RESPONSE; DRUG ADMINISTRATION; EVALUATION STUDY; LUPUS ERYTHEMATOSUS, CUTANEOUS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMALARIALS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84960462608     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2015.09.064     Document Type: Article

References (29)

1. H.Y. Schultz, J.P. Dutz, F. Furukawa, and et al. From pathogenesis, epidemiology, and genetics to definitions, diagnosis, and treatments of cutaneous lupus erythematosus and dermatomyositis: a report from the III International Conference on Cutaneous Lupus Erythematosus (ICCLE) 2013 J Invest Dermatol 135 1 2015 7 12
2. N. Ezra, and J. Jorizzo Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus Clin Exp Dermatol 37 4 2012 327 334
3. M.N. Islam, M. Hossain, S.A. Haq, M.N. Alam, P.M. Ten Klooster, and J.J. Rasker Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus Int J Rheum Dis 15 1 2012 62 68
4. I. Cavazzana, R. Sala, C. Bazzani, and et al. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine Lupus 18 8 2009 735 739
5. J. Cortés-Hernández, M. Torres-Salido, J. Castro-Marrero, M. Vilardell-Tarres, and J. Ordi-Ros Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome Br J Dermatol 166 3 2012 616 623
6. C. Francès, A. Cosnes, P. Duhaut, and et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study Arch Dermatol 148 4 2012 479 484
7. M.F. Marmor, U. Kellner, T.Y.Y. Lai, J.S. Lyons, and W.F. Mieler American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy Ophthalmology 118 2 2011 415 422
8. D.E. Furst, H. Lindsley, B. Baethge, and et al. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension Arthritis Rheum 42 2 1999 357 365
9. R.B. Melles, and M.F. Marmor The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy JAMA Ophthalmol 132 12 2014 1453 1460
10. M.F. Marmor, R.E. Carr, M. Easterbrook, A.A. Farjo, and W.F. Mieler American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology Ophthalmology 109 7 2002 1377 1382
11. N. Costedoat-Chalumeau, B. Dunogué, G. Leroux, and et al. A critical review of the effects of hydroxychloroquine and chloroquine on the eye Clin Rev Allergy Immunol 49 3 2015 317 326
12. S.E. Tett, D.J. Cutler, R.O. Day, and K.F. Brown A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers Br J Clin Pharmacol 26 3 1988 303 313
13. J. Albrecht, L. Taylor, J.A. Berlin, and et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus J Invest Dermatol 125 5 2005 889 894
14. A. Kuhn, A.M. Meuth, D. Bein, and et al. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus Br J Dermatol 163 1 2010 83 92
15. N. Costedoat-Chalumeau, Z. Amoura, J.-S. Hulot, and et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus Arthritis Rheum 54 10 2006 3284 3290
16. A. Kuhn, and A. Landmann The classification and diagnosis of cutaneous lupus erythematosus J Autoimmun 48-49 2014 14 19
17. R. Klein, S. Moghadam-Kia, J. LoMonico, and et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus Arch Dermatol 147 2 2011 203 208
18. M. Petri, A.-M. Orbai, G.S. Alarcón, and et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus Arthritis Rheum 64 8 2012 2677 2686
19. N. Costedoat-Chalumeau, J. Pouchot, G. Guettrot-Imbert, and et al. Adherence to treatment in systemic lupus erythematosus patients Best Pract Res Clin Rheumatol 27 3 2013 329 340
20. S.E. Tett, R.O. Day, and D.J. Cutler Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis-a cross sectional study J Rheumatol 20 11 1993 1874 1879
21. + lymphocytes in hydroxychloroquine-treated lupus patients Ann N Y Acad Sci 1108 2007 41 50
22. M. Jallouli, L. Galicier, N. Zahr, and et al. Determinants of hydroxychloroquine blood concentration variation in systemic lupus erythematosus Arthritis Rheumatol 67 2015 2176 2184
23. N. Costedoat-Chalumeau, L. Galicier, O. Aumaître, and et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicenter controlled trial (PLUS Study) Ann Rheum Dis 72 11 2013 1786 1792
24. M.W.P. Tsang-A-Sjoe, I.E.M. Bultink, and A.E. Voskuyl Long-term evaluation of antimalarials in a Dutch SLE cohort: intolerance and other reasons for non-use Clin Exp Rheumatol 32 1 2014 95 100
25. F. Wolfe, and M.F. Marmor Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus Arthritis Care Res 62 6 2010 775 784
26. J.S. Lyons, and M.L. Severns Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review: review of mfERG ring ratios in Plaquenil toxicity Doc Ophthalmol Adv Ophthalmol 118 1 2009 29 36
27. I. Ingster-Moati, M. Crochet, E. Manchon, and et al. Analysis of 925 patients on long-term hydroxychloroquine or chloroquine treatment: results of ophthalmological screening [in French] J Fr Ophtalmol 27 4 2004 367 373
28. N. Costedoat-Chalumeau, V. Le Guern, and J.-C. Piette Determining adherence to therapeutic regimens in patients with chronic illness: comment on the article by Waimann et al Arthritis Rheumatol 66 3 2014 770
29. A. Kuhn, V. Ruland, and G. Bonsmann Cutaneous lupus erythematosus: update of therapeutic options part I J Am Acad Dermatol 65 6 2011 e179 e193